Supanote

Bottom line

Supanote AI markets itself as a therapy-specific ambient clinical documentation tool with native EHR write-back through a feature called Super Fill. The pitch is narrow: behavioral health clinicians tired of post-session charting can offload note generation to an AI scribe purpose-built for psychotherapy workflows. On paper, this specialization is promising. Therapy notes differ structurally from medical notes, and a tool designed for treatment plans, interventions, and mental status exams might outperform general-purpose scribes retrofitted for mental health. However, prospective buyers face a critical obstacle: Supanote operates with near-zero public evidence. No peer-reviewed validation studies, minimal clinician testimonials, and sparse third-party coverage make it impossible to verify vendor claims with the rigor expected in YMYL healthcare purchasing.

Pricing information is contradictory. The vendor lists a free tier at zero dollars per month alongside a parenthetical note suggesting typical costs fall between thirty and fifty dollars monthly per clinician. Contract terms, seat minimums, implementation fees, and support costs remain undisclosed. Compliance certifications such as HIPAA attestation, SOC 2 audit status, HITRUST certification, and FDA clearance are not surfaced in publicly available materials. The list of compatible EHRs and the depth of Super Fill integration (read-only versus bi-directional write) are similarly opaque. For a CMIO evaluating vendor risk, these omissions are disqualifying without direct vendor engagement and contractual guarantees.

The verdict is therefore cautious and conditional. Solo behavioral health clinicians or small group practices willing to adopt early-stage tools with unproven track records may find value if direct vendor demos satisfy integration and compliance questions. Larger IDNs, academic medical centers, and risk-averse practices should defer adoption until the vendor publishes validation data, surfaces customer references, and clarifies pricing and compliance posture. This is not a tool to deploy organization-wide without a pilot cohort and rigorous internal evaluation. The therapy-specific positioning is intellectually coherent, but execution evidence is missing.

Why we picked it

Supanote earns attention not because it has proven superiority, but because it represents a clinically rational design hypothesis that deserves testing. Most ambient documentation tools on the market in 2026 are generalists. Nuance DAX, Suki AI, Abridge, and DeepScribe serve multi-specialty clinics and hospital systems. Their training data spans emergency medicine, primary care, cardiology, and orthopedics. Therapy notes are an afterthought in these platforms, forcing behavioral health users to retrofit tools designed for physical diagnoses and procedural documentation. Supanote's stated focus on psychotherapy workflows suggests the vendor understands that mental health charting has distinct requirements: treatment plan updates, risk assessments, therapeutic modalities, mental status exams, and session content that is conversational rather than procedural.

The Super Fill EHR write-back feature, if it performs as marketed, addresses a major pain point. Many AI scribes generate a note that clinicians must manually copy into their EHR, a friction point that negates time savings. Native EHR integration that populates structured fields directly is a meaningful workflow improvement. Whether Super Fill supports major behavioral health EHRs like SimplePractice, TherapyNotes, Valant, or Osmind is unknown. The vendor does not publish a compatibility matrix. If integration is limited to a narrow EHR subset or requires custom API work per practice, the deployment value proposition weakens significantly.

We include Supanote in this review because the therapy-specific positioning is underserved in the ambient documentation market. Freed began with a therapy focus before expanding to general medical specialties. Elation and SimplePractice offer AI-assisted notes within their EHR ecosystems but are not standalone ambient scribes. A dedicated therapy scribe that integrates across multiple EHRs would fill a real gap. The question is whether Supanote delivers on that promise with sufficient quality, compliance rigor, and vendor stability to justify adoption risk.

The decision to review this tool despite thin evidence reflects the reality that early-stage healthtech often reaches clinicians before validation studies catch up. CMIOs and practice managers evaluating Supanote should treat this as a preliminary assessment pending vendor-supplied evidence. This is not a tier-one recommendation. It is a watchlist entry for practices that can tolerate pilot risk and have internal resources to evaluate independently.

What it does well

The therapy-specific design intent, if executed competently, offers structural advantages over general-purpose scribes. Psychotherapy sessions are predominantly conversational. A scribe trained to recognize cognitive-behavioral interventions, psychodynamic themes, motivational interviewing techniques, and crisis assessments should theoretically produce more accurate session summaries than a tool trained on surgical consults and medication reconciliation. Whether Supanote's underlying model achieves this differentiation is unverifiable without access to sample outputs or validation metrics. Vendor materials do not include note accuracy benchmarks, inter-rater reliability comparisons, or clinician time-savings data.

The Super Fill EHR write-back feature, assuming it functions as described, eliminates the copy-paste step that plagues competing products. Clinicians using Suki AI or Abridge often generate a high-quality note in the scribe interface, then manually transfer it into their EHR's progress note fields. This adds thirty to ninety seconds per encounter and reintroduces transcription errors. A true bi-directional EHR integration that maps AI-generated content directly into structured fields (chief complaint, assessment, plan, interventions, next appointment) is clinically valuable. The unknown variable is whether Super Fill achieves this depth or merely pastes unstructured text into a single free-text box.

Ambient listening tools succeed when they reduce after-hours documentation burden. Behavioral health clinicians report spending ten to thirty minutes per session on note completion, often extending workdays into evenings. If Supanote reduces this to under five minutes per session while maintaining note quality sufficient for billing compliance, insurance audits, and continuity of care, the time savings compound meaningfully. A clinician seeing twenty patients weekly saves two to eight hours per week. This ROI math justifies a thirty to fifty dollar monthly subscription if the tool actually delivers. The conditional clause is critical: no independent validation confirms these time savings.

The free tier pricing, if accurate and not a promotional placeholder, lowers the barrier to pilot testing. Practices can trial the tool without upfront financial risk. However, feature limitations on the free tier are not disclosed. If core functionality like Super Fill EHR write-back is paywalled, the free tier is effectively a demo rather than a usable product. Transparency on tier-specific feature availability is absent from public materials.

Where it falls short

The evidence gap is disqualifying for risk-averse buyers. Zero peer-reviewed publications means no external validation of note accuracy, clinical safety, or workflow impact. The PubMed index contains no studies evaluating Supanote in real-world therapy settings. This is not unusual for early-stage healthtech, but it places the burden of validation entirely on the purchasing organization. A CMIO cannot cite external studies when justifying budget allocation or presenting to a medical executive committee. Competing tools like Nuance DAX and Suki AI have published case studies, academic partnerships, and third-party evaluations. Supanote does not.

Clinician testimonials are nearly absent. A scan of behavioral health forums, Reddit communities like r/psychotherapy and r/therapists, and professional social media yields minimal discussion. The three Reddit mentions in aggregated sentiment data do not clearly reference Supanote; quoted language about Jira issues and meeting notes suggests data contamination from unrelated workflow tools. Without verified user feedback, prospective buyers cannot assess real-world satisfaction, edge case failures, or specialty-specific fit. Vendor-curated testimonials on the Supanote website, if present, lack third-party verification and should be treated as marketing rather than evidence.

Compliance certifications are not publicly documented. HIPAA compliance is table stakes for any clinical documentation tool, but attestation alone is insufficient. SOC 2 Type II audits, HITRUST certification, and ISO 27001 demonstrate operational security rigor that large health systems require. FDA clearance status is relevant if the vendor markets Supanote as a clinical decision support tool or if AI-generated notes influence diagnosis or treatment. The regulatory posture is unclear. Without these certifications surfaced in vendor materials, IT security teams cannot complete due diligence, and legal teams cannot approve procurement contracts.

EHR integration depth is the critical unknown. The Super Fill feature is described as native write-back, but compatible EHR vendors are not named. Behavioral health practices use a fragmented EHR landscape: SimplePractice, TherapyNotes, Valant, Osmind, Elation, Headway, and others. If Supanote integrates with only one or two, most practices are excluded. If integration requires custom API development per EHR, implementation costs and timelines balloon. Competing tools like Notable and Freed publish EHR compatibility matrices. Supanote's omission of this information is a red flag. A buyer cannot evaluate fit without knowing if their existing EHR is supported.

Deployment realities

Implementation complexity is unknowable without vendor engagement. If Super Fill requires API credentials, HL7 interface setup, or FHIR endpoint configuration, deployment demands IT staff hours. Solo practices without dedicated IT support may find installation prohibitive. If integration is plug-and-play via OAuth or pre-built EHR app marketplaces, deployment is trivial. The vendor does not publish implementation guides, support documentation, or onboarding timelines. A reasonable assumption is that deployment difficulty scales with EHR complexity. Practices using cloud-native EHRs with open APIs will fare better than those on legacy on-premises systems.

Clinician training time is another unknown variable. Ambient scribes require behavior change: clinicians must remember to activate recording, speak clearly, and review AI-generated notes for accuracy before signing. Training overhead for tools like Nuance DAX averages thirty to sixty minutes per clinician, with additional time for workflow adjustment over the first week. If Supanote requires comparable training, practices must budget onboarding time during the pilot phase. If the tool is intuitive enough to require only a ten-minute walkthrough, adoption friction is minimal. Vendor materials do not specify training requirements or provide clinician onboarding resources.

Change management is a hidden cost. Introducing an AI scribe shifts clinical workflows. Support staff may need retraining if note-generation responsibilities move from medical assistants to automated systems. Billing and compliance teams must verify that AI-generated notes meet payer documentation requirements and pass insurance audits. If a practice's first AI-generated note triggers a claim denial or audit flag, confidence in the tool collapses. A staged rollout with internal quality review is prudent, but this extends the timeline before full deployment. Practices should plan for a three-month pilot phase minimum, even if the tool technically deploys in days.

Pricing realities

The pricing model is contradictory and opaque. Official tier data lists zero dollars per month for the base plan, but a parenthetical note indicates typical costs between thirty and fifty dollars monthly per clinician. This discrepancy suggests either promotional pricing, feature-limited free tier, or incomplete public disclosure. Without clarity on what the free tier includes, buyers cannot assess value. If Super Fill EHR write-back is paywalled behind the paid tier, the free plan is a demo rather than a functional product. If the free tier is fully functional but limits session volume or note count, solo practitioners might stay on free indefinitely while group practices must pay.

Hidden costs are not surfaced. Does the vendor charge per API call for EHR write-back? Are there per-session usage fees beyond a monthly cap? Implementation fees, onboarding support, customer success manager access, and annual contract lock-ins are common in healthtech SaaS pricing but not disclosed in public materials. Competing tools like Suki AI charge per clinician per month with tiered support levels. Notable offers usage-based pricing tied to encounter volume. Freed markets a flat monthly rate with unlimited sessions. Supanote's model is unclear, making side-by-side cost comparisons impossible.

ROI math depends on time savings that are unverified. If the tool reduces post-session documentation from twenty minutes to five minutes, a clinician seeing twenty patients weekly saves five hours per week. At a clinician hourly rate of one hundred fifty dollars, that is seven hundred fifty dollars in recaptured productivity weekly, or three thousand dollars monthly. A fifty-dollar subscription is trivial against that ROI. However, if the tool saves only five minutes per session or introduces review overhead that negates savings, the ROI collapses. Without validation data, practices should pilot internally with time-tracking before committing to annual contracts.

Compliance + integration depth

HIPAA compliance is presumably present but not explicitly documented in accessible vendor materials. Any tool handling protected health information must have a business associate agreement, encryption in transit and at rest, access logging, and breach notification procedures. The absence of a public security whitepaper or trust center page is concerning. Large health systems require vendors to complete security questionnaires covering incident response, penetration testing, employee background checks, and third-party audits. Without these materials pre-published, procurement cycles extend as IT security teams chase documentation.

SOC 2 Type II audit status is the industry standard for healthtech SaaS but not confirmed for Supanote. This audit verifies that vendor controls for security, availability, processing integrity, confidentiality, and privacy are designed and operating effectively over time. HITRUST certification, a higher bar common among EHR vendors and enterprise healthtech, is also unconfirmed. The absence of these certifications does not mean the vendor is non-compliant, but it shifts validation burden to the buyer. A CMIO cannot check a compliance box without audited proof. Competing tools like Nuance DAX and Suki AI publish SOC 2 reports and HITRUST certification publicly.

EHR integration depth is the decisive factor for workflow fit. If Super Fill supports only unstructured text paste into a single note field, it is no better than manual copy-paste. If it maps AI-generated content into discrete EHR fields (subjective, objective, assessment, plan, next appointment, billing codes), it delivers real workflow improvement. Bi-directional integration that pulls patient context from the EHR (prior diagnoses, medications, treatment history) into the AI scribe would enhance note accuracy. Whether Supanote achieves this depth is unknown. Vendor demonstrations and pilot testing are required to confirm. Practices should specifically test Super Fill with their existing EHR before signing contracts.

Vendor stability + roadmap

Vendor background is minimally documented. Supanote AI as a corporate entity lacks publicly disclosed funding rounds, leadership team profiles, customer counts, or office locations. This opacity is common among early-stage healthtech startups but raises buyer risk. A practice adopting Supanote is betting on vendor longevity. If the company shuts down, pivots to a different market, or is acquired and sunsetted, EHR integration breaks and workflows collapse. Competing tools backed by Microsoft (Nuance DAX) or with disclosed Series B funding (Suki AI) offer more stability confidence.

Customer references are absent from public materials. Vendor websites for established competitors typically showcase named health systems, academic medical centers, or professional societies that endorse the tool. Supanote does not publish customer logos, case studies, or testimonial videos. Without verifiable users, buyers cannot perform reference checks or peer network inquiries. A CMIO considering Supanote should request a list of current customers, contact at least three, and ask pointed questions about implementation challenges, billing compliance, and vendor responsiveness.

Product roadmap is undisclosed. Does the vendor plan to expand beyond behavioral health into other specialties? Will Super Fill integration extend to additional EHRs? Are there plans for features like patient-facing session summaries, treatment plan tracking, or insurance pre-authorization automation? Roadmap visibility helps buyers assess whether the vendor's future direction aligns with practice needs. If the vendor pivots away from therapy toward general medical notes, early therapy-focused adopters may find support deprioritized. Without public roadmap communication, buyers adopt blind to future direction.

How it compares

Nuance DAX Copilot, Microsoft-backed and Epic-integrated, is the enterprise-grade standard. It supports multi-specialty workflows, has published validation studies, and integrates deeply with Epic EHRs via ambient listening and auto-generated notes. However, it is overkill for solo behavioral health practices, requires Epic infrastructure, and costs significantly more than thirty to fifty dollars per clinician monthly. Supanote's therapy-specific positioning and lower price point target a different buyer: small practices outside large IDNs. DAX wins for scale and integration depth; Supanote theoretically wins for therapy-specific workflow fit and affordability.

Suki AI is a voice-first generalist scribe used across primary care, specialty clinics, and hospital settings. It supports multiple EHRs via dictation and note generation but lacks Supanote's claimed therapy-specific training. Suki publishes case studies and has a disclosed customer base exceeding thousands of clinicians. Pricing is approximately one hundred dollars per clinician per month, higher than Supanote's suggested range. Suki wins on evidence and vendor stability; Supanote theoretically wins on therapy workflow specialization and cost. However, without validation data, this trade-off is speculative.

Freed started as a therapy-focused AI scribe before expanding to general medical specialties. It offers flat-rate pricing around one hundred dollars monthly with unlimited sessions, EHR integrations via copy-paste or API, and a growing customer base among behavioral health clinicians. Freed has published user testimonials and maintains an active community forum. If Freed's therapy-specific features are comparable to Supanote's, Freed wins on evidence, transparency, and community trust. Supanote's edge would be lower cost and potentially deeper EHR integration via Super Fill, but this advantage is unproven.

SimplePractice and TherapyNotes are EHR platforms with integrated AI note-generation features. They do not require standalone scribe subscriptions but lock users into their EHR ecosystems. Clinicians already using these EHRs should evaluate built-in AI features before adopting a third-party tool like Supanote. If Supanote integrates with these EHRs and offers superior note quality, it becomes a viable add-on. If integration is absent or redundant with native EHR features, Supanote has no differentiation. Compatibility clarity is essential for this competitive positioning.

What clinicians say

Clinician feedback on Supanote is nearly nonexistent in public forums. A search of behavioral health communities on Reddit, including r/psychotherapy, r/therapists, and r/clinicalpsych, yields no substantive discussion of the tool. The three aggregated Reddit mentions provided in source materials do not clearly reference Supanote; quoted language about Jira issues, meeting notes, and project specs suggests data sourced from software development or project management contexts rather than clinical documentation. This is a red flag indicating either extremely low adoption or misattributed sentiment data.

One paraphrased theme mentions reducing late-night catchup hours and smoothing team workflows. If this references Supanote, it aligns with the value proposition of time savings. However, without verifiable attribution, this cannot be treated as reliable user feedback. Another theme notes context fragmentation across tools and reliance on tribal knowledge, which would be a criticism of workflow integration failures. If this applies to Supanote, it suggests Super Fill EHR write-back does not fully unify documentation workflows as marketed.

The absence of verified clinician testimonials is unusual for a tool marketed to time-starved practitioners. Competing products feature video testimonials, written reviews, and active user communities. Supanote's invisibility in these channels suggests either very early-stage market presence or limited traction. Prospective buyers should request access to a user reference group directly from the vendor before committing. Without peer validation, adoption is a leap of faith rather than an evidence-based decision.

What the literature says

Supanote has zero coverage in peer-reviewed medical literature. A PubMed search returns no studies evaluating the tool's accuracy, clinical safety, workflow impact, or billing compliance. This is not atypical for early-stage healthtech, but it leaves buyers without independent validation. Competing tools like Nuance DAX have published studies in journals like JMIR and NPJ Digital Medicine demonstrating time savings, clinician satisfaction, and note quality benchmarks. Suki AI has partnered with academic medical centers to produce validation data. Supanote has not.

The absence of literature coverage means key questions remain unanswered. What is the note accuracy rate compared to human-transcribed notes? How often do AI-generated therapy notes contain clinically significant errors? Do notes meet payer documentation requirements and pass insurance audits? Are there specialty-specific failure modes, such as misidentifying cognitive-behavioral techniques or misrepresenting risk assessments? Without published answers, practices must validate internally during pilots. This extends timelines and increases adoption risk.

The evidence gap is particularly concerning for a tool handling sensitive mental health information. Therapy notes include crisis assessments, suicidality screens, trauma disclosures, and treatment-resistant conditions. An AI scribe error that omits a safety concern or misrepresents clinical judgment could have medico-legal consequences. Peer-reviewed validation provides external assurance that the tool has been stress-tested in real-world conditions. Supanote lacks this assurance. Until published studies confirm safety and accuracy, conservative buyers should treat the tool as experimental.

Who it's for

Solo behavioral health clinicians in private practice are the narrowest fit. Therapists, psychologists, LCSWs, and psychiatrists seeing fifteen to thirty patients weekly who spend significant after-hours time on documentation may benefit if Supanote delivers on time-savings claims. The low suggested price point (thirty to fifty dollars monthly) is accessible for solo practitioners, and the therapy-specific design aligns with workflow needs. However, these clinicians must tolerate adoption risk: no peer validation, minimal compliance transparency, and unknown EHR compatibility. This is a tool for early adopters comfortable piloting unproven technology.

Small group practices with two to ten clinicians face similar trade-offs. If the practice uses an EHR compatible with Super Fill and can dedicate internal resources to pilot testing, Supanote could streamline documentation across the group. The cost scales linearly per clinician, remaining affordable relative to competing enterprise tools. However, practices without dedicated IT support may struggle with implementation if EHR integration is complex. A three-month pilot with one or two clinicians is advisable before full rollout.

Large IDNs, academic medical centers, and health systems should defer adoption. The evidence gap, compliance opacity, and vendor stability uncertainty are unacceptable risks at scale. These organizations require validated tools, disclosed customer references, SOC 2 certification, and contractual service-level agreements. Supanote does not meet enterprise procurement standards. CMIOs evaluating ambient documentation should prioritize tools like Nuance DAX or Suki AI with proven track records, published validation, and multi-year customer retention data.

Clinicians outside behavioral health should skip Supanote entirely. The tool is marketed as therapy-specific, and there is no indication it supports primary care, emergency medicine, surgery, or other specialties. Attempting to use it outside its intended domain will produce poor results. Multi-specialty practices should adopt a generalist tool like Abridge or Notable rather than deploying specialty-specific scribes per department.

The verdict

Supanote AI is an intellectually coherent product hypothesis with insufficient execution evidence. The therapy-specific positioning addresses a real gap in the ambient documentation market, and the Super Fill EHR write-back feature solves a genuine workflow pain point. However, zero peer-reviewed validation, near-absent clinician testimonials, opaque compliance certifications, contradictory pricing, and minimal vendor transparency make this a high-risk adoption for all but the most risk-tolerant early adopters. A practice betting on Supanote is betting on a vendor's roadmap and execution without external proof that either will materialize.

For solo behavioral health clinicians willing to pilot experimental tools, Supanote is worth a controlled trial if the vendor demonstrates EHR compatibility and provides a business associate agreement. Run a three-month pilot with time-tracking to confirm actual documentation time savings. Review every AI-generated note for accuracy before signing, and monitor for billing compliance issues. If the tool saves five or more hours weekly without quality degradation, it justifies the subscription cost. If it introduces errors, requires extensive editing, or fails to integrate cleanly with your EHR, terminate immediately.

For group practices and larger organizations, defer adoption until the vendor publishes validation data, customer references, and compliance certifications. Request a detailed demo that includes live Super Fill EHR write-back with your specific EHR instance. Ask for SOC 2 and HITRUST documentation. Contact at least three current customers and inquire about implementation timelines, support responsiveness, and hidden costs. If the vendor cannot provide these materials, walk away. Competing tools with established track records are safer bets. If Supanote demonstrates compelling differentiation after transparency improvements, revisit in twelve months.